Synmosa Biopharma (4114) — Long-term Investment Intensity
Synmosa Biopharma (4114) has a Long-term Investment Intensity of 6.7% as of September 2019. Long-term investments of NT$581.80 Million represent 6.7% of total assets of NT$8.70 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Synmosa Biopharma (4114) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Synmosa Biopharma Long-term Investment Intensity (2015–2018)
This chart shows how Synmosa Biopharma's Long-term Investment Intensity has evolved across 4 annual periods from 2015 to 2018. As of September 2019, the intensity stands at 6.7%, reflecting long-term investments of NT$581.80 Million against total assets of NT$8.70 Billion TWD. Explore Synmosa Biopharma debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Synmosa Biopharma (2015–2018)
The table below presents the year-by-year Long-term Investment Intensity for Synmosa Biopharma from 2015 to 2018, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 4114 market cap.
| Year | LT Investment Intensity | LT Investments (TWD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 7.1% | NT$536.72 Million | NT$7.54 Billion | ▼ -3.8 pp |
| 2017 | 10.9% | NT$818.65 Million | NT$7.50 Billion | ▲ +1.9 pp |
| 2016 | 9.0% | NT$612.26 Million | NT$6.79 Billion | ▼ -2.1 pp |
| 2015 | 11.1% | NT$511.69 Million | NT$4.59 Billion | — |